A Phase 1, Randomized, Double Blind, Placebo Controlled, Multiple Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With VX-661/Ivacaftor in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Olacaftor (Primary) ; Ivacaftor/tezacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 27 Mar 2018 Status changed from recruiting to completed.
- 27 Apr 2016 Status changed from not yet recruiting to recruiting, as reported by Vertex media release.
- 30 Oct 2015 New trial record